A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Phase 1
241
about 7.4 years
18+
20 sites in CA, FL, IN +10
About this study
This trial is testing a treatment called LY4337713 for people with certain types of cancer that have spread or are advanced. The goal is to see if the treatment is safe, what side effects it might cause, and how well it works. Each participant will be in it for about 5 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY4337713
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities, Phase 1b: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)
Secondary: Phase 1a and 1b: Duration of Response (DOR), Phase 1a and 1b: Percentage of Participants with Disease Control Rate (DCR), Phase 1a and 1b: Time to Response (TTR), Phase 1a: Number of Participants with Best Overall Response (BOR), Phase 1a: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR), Phase 1a: PK: Area Under the Concentration Time Curve (AUC) of LY4337713, Phase 1a: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4337713
Oncology